Nanobiotix Raises $71 Million from HealthCare Royalty to Accelerate Cancer Drug Development

Nanobiotix has secured $71 million through a royalty monetization deal with HealthCare Royalty to speed up the development and commercialization of its oncology treatments. Nanobiotix $71 million funding will support the advancement of NBTXR3, its lead radioenhancer therapy, designed to improve outcomes for cancer patients. This strategic partnership strengthens Nanobiotix’s financial position and enables broader clinical expansion while reinforcing its commitment to innovative cancer care solutions.


https://patentmonetize.com/nan....obiotix-royalty-mone